Treatment, arranged by how much proof stands behind it

Four things settled before a treatment is chosen

The first decision is not which treatment but which condition. Categories I and II are infections of the gland, so the work is to identify the organism and let a clinician choose an antibiotic that reaches prostatic tissue. Category III, which is around nine in ten diagnoses, is not an infection, and the object changes: to establish which mechanisms are producing symptoms in one particular person and to address several at once. Category IV ordinarily needs nothing. One classification therefore produces three unrelated plans, which is why any page offering “the treatment for prostatitis” as a single list has skipped the question that governs the rest. How a category is reached is covered in note 02, on tests and causes.

The second point resists cushioning. No treatment is established as a reliable cure for chronic prostatitis / chronic pelvic pain syndrome. European and American urological guidance says so in those terms, and the systematic reviews underneath it agree. The realistic target is a reduction in symptom burden: less pain, fewer ruined weeks, sleep that survives the night. Many people reach that, and the distance between it and a promise of permanent resolution is where most of the untrustworthy material on this subject lives.

The remaining two concern method. Single agents tested against a dummy tablet in unselected participants have returned small average effects over and over, because those participants are several different problems under one label; addressing two or three of an individual’s active mechanisms does better than any one alone. And anything begun needs a fair run before it is judged, since symptoms rise and fall in waves for no visible reason. Guidance discusses weeks rather than days, and the decision to start, continue or stop belongs with the clinician who holds your history.

Antibiotics: essential twice, counter-productive often

For the two bacterial categories, antibiotics are the treatment and nothing substitutes for them. In the acute form the matter is urgent: an organism is multiplying in the gland, and the complications — pus collecting and needing drainage, a bladder that stops emptying, infection reaching the bloodstream — arrive within days. In the chronic bacterial form the organism shows up on cultures that localise it to the prostate rather than the bladder, and the obstacle is penetration: agents differ greatly in how much of them crosses into prostatic fluid. Guidance discusses longer courses here than a bladder infection would warrant, and treats a relapse as grounds for a fresh culture.

The trouble sits with Category III. No organism can be demonstrated, repeated culturing does not change that, and placebo-controlled trials in men who have already had a course find no benefit worth describing. Antibiotics are nonetheless among the most prescribed treatments for the chronic pain form. The reasons are human: the word itself announces an infection; symptoms wax and wane, so improvement after a course is credited to the course; and both people in the room would rather do something than nothing.

Repetition carries costs that are usually left out. Antibiotic classes have their own adverse effects, some awkward and a few serious, and the gut population is measurably disturbed for months after a course ends, with digestive consequences that confuse an already difficult picture. Resistance is selected for in the individual as well as accumulated across the population. And the months go on waiting for a drug to act rather than on approaches that carry support.

None of that makes the first course unreasonable. Before localisation testing a bacterial cause cannot be excluded, some men do improve, and guidance accepts an initial trial on those grounds. What the evidence does not support is the fourth and fifth course in someone whose cultures have been clean throughout. In that loop the question worth raising is not which antibiotic comes next but whether the category has ever been settled.

Six domains in place of one diagnosis

Research into the chronic pain form spent years treating it as a single disease, testing one treatment at a time against everybody who carried the label and producing a run of near-misses and contradictory trials. The explanation now generally accepted is that the label covers several distinct problems, so averaging across them dilutes a real effect in one subgroup until it disappears.

So the practice became to describe a person before treating them. The best-known framework, set out in the urological literature in 2009 and carried into later guidance, is UPOINT: six domains — urinary, psychosocial, organ-specific, infection, neurological or systemic, and tenderness of the skeletal muscles — each marked present or absent from the history, the examination and the tests already done. Treatment is aimed only at the domains that are positive, which is why profiling leads almost automatically to combinations rather than to a single prescription. Unfamiliar terms are defined in the word list.

The number of positive domains tracks reasonably well with symptom severity, which helps explain why one case is harder to shift than another. The honest qualification is that the framework has never been tested in a large randomised comparison against unstructured care; its standing rests on observational series and on the plainer fact that it stops a clinic giving everybody the same thing and hoping.

The medicine classes, and the weight behind each

Nearly every medicine used for the chronic pain form was developed for something else and is borrowed on the argument that one of its actions ought to help here too; sometimes that argument survives a trial and sometimes it does not. The table gives what each class is intended to do, and the direction of the evidence in plain words rather than in grades that would imply a precision this literature lacks.

Two qualities of this literature travel with any such table. The first is inconsistency: a promising small trial is routinely followed by a larger one that finds nothing, and alpha-blockers illustrate it best, reported as useful and as useless depending on which men were enrolled. The second is the scale of the placebo response, which in trials of this condition commonly reaches about a third of the dummy-treatment group reporting meaningful improvement — the reason comparison groups exist, and the reason testimony cannot replace them. Phytotherapy needs one line more: preparations sold for this purpose are regulated as food supplements rather than as medicines in most countries, so the contents need not match what was used in any published trial, and anything of the kind is worth raising at an appointment first.

Working on the pelvic floor itself

Of everything on this page, treatment directed at the pelvic muscles has the most encouraging evidence for the chronic pain form, though what it outperforms is other conservative treatment and the trials are small by the standards of other specialties. The reasoning begins with what an examination finds: a pelvic floor that is typically too tight rather than too weak, held in a low-level contraction the person is unaware of, with tender bands that reproduce the familiar pain when pressed and refer it into the penis, a testicle or the rectum. Muscle kept short becomes painful in its own right and makes the release needed to empty the bladder harder to coordinate, which accounts for a symptom set in which pain, urinary difficulty and discomfort with ejaculation arrive together while every test of the gland reads as unremarkable.

It also explains the commonest self-inflicted setback. Clench-and-release exercises are widely publicised and designed for a weak floor, usually after prostate surgery or for incontinence; applied to a floor already over-contracted they add contraction to contraction, and men not infrequently report symptoms worsening on exactly such a programme. The work here runs the other way — learning to let go, releasing tender points by hand, retraining the coordination of emptying. A trial run through the US research network found that targeted myofascial therapy produced a notably higher rate of reported improvement than general relaxation massage, which is the comparison that matters.

Around that sit simpler measures with modest but real support: local heat, pacing so that a good day is not spent generating three bad ones, and graded exercise, meaning an amount of movement that can be sustained and raised slowly. Internal pelvic floor work is a specialised skill, so asking what training a practitioner has in it is reasonable.

The nervous system, sleep, and the stigma problem

This section has to begin by disposing of a misunderstanding, or its contents will not be read. Treatment aimed at how pain is processed is not a statement that the pain is imaginary. Pain is produced by a nervous system, and in persistent pain conditions that system often becomes more sensitive, amplifying ordinary signals from the bladder, bowel and muscles into signals registered as pain. The amplification is a physical process, and work directed at it is work on a real mechanism. A man told his pain is “stress” and sent away has been dismissed; a man offered treatment for pain amplification alongside everything else has been taken seriously. The two sound alike in a hurried consultation and are opposites.

The components themselves are unremarkable. Pain education — an account of what is driving the symptoms and what they do not signify — reduces the fear that makes pain worse. Cognitive behavioural approaches have reasonable support across persistent pain generally and are increasingly offered within this condition, aimed at the catastrophic thinking and activity avoidance that reliably enlarge a symptom. Sleep deserves attention in its own right, since poor sleep measurably lowers pain thresholds and the relationship runs both ways. Stress regulation of whatever kind a person will keep up has a place, not because stress causes the condition but because it modulates the pain.

Depression and anxiety are commoner in men with long-standing pelvic pain than in the general population, and warrant treating in their own right; for entrenched cases the appropriate destination is a multidisciplinary pain service.

Injections, neuromodulation, and the limits of surgery

Procedures sit at the end of this note because they carry more risk than anything above them and, for the chronic pain form, less proof; they belong in a specialist setting, once the conservative approaches have been worked through without enough benefit. Nerve blocks and injections into tender points are used both to interrupt a pain cycle and, when the response is informative, to help locate where the pain comes from, though the published evidence is mainly small series rather than substantial randomised trials and the benefit is frequently temporary. Neuromodulation — mild electrical stimulation of the nerves supplying the pelvis, through an implanted device or a simpler technique applied at the ankle — has firmer standing in bladder conditions than in pelvic pain, where it remains promising in parts and far from established.

Surgery needs the plainest statement on the page. There is no established role for an operation on the prostate in chronic prostatitis / chronic pelvic pain syndrome. Operations exist for the bacterial categories and for specific structural findings: draining a collection of pus in the acute form, relieving a bladder that will not empty, treating a narrowed urethra, and rarely removing infected stones in the gland that keep an infection alive. Each of those addresses a demonstrated physical problem; where none has been demonstrated the logic collapses, for a reason that fits in one line. An operation on a gland that is not the source of the pain cannot be expected to relieve the pain, and it carries its own risks to continence and sexual function.

Claims that deserve suspicion

Because the condition is persistent, poorly understood by the public and attached to a good deal of embarrassment, it attracts commercial attention of a particular kind. None of the following proves bad faith, but each marks a gap between what is claimed and what the evidence licenses.

• A cure is guaranteed. Nothing has been shown to reliably cure the chronic pain form, so a guarantee is a claim about marketing rather than outcomes, and it contradicts every major guideline on the subject.
• The method is secret or proprietary. Treatments that work are described openly so that others can test them; a protocol available only from its originator has avoided the one process that would establish whether it does anything.
• A supplement is central to the plan. An own-brand preparation sold alongside a consultation creates an obvious conflict of interest, and supplement regulation does not require the contents to be shown to work.
• A diagnosis arrives from a website questionnaire. The categories are separated by cultures taken in sequence, examination and sometimes imaging; no set of form answers distinguishes a relapsing infection from a sensitised pelvic floor.
• Testimonials replace trial data. With about a third of placebo recipients improving in trials here, a page of grateful accounts is what an inert treatment also generates. Ask what happened in the comparison group.
• Payment comes before assessment. Pressure to buy a package before anyone has examined you or taken a history inverts the order in which care is meant to happen.

The markers of a sound source are duller: it names the guidance it relies on, it distinguishes the four categories, it says where the evidence is weak, and it has nothing to sell you. Our own method is written up here.

Treatment is the part of this subject that happens in a clinic. The part that happens in a kitchen, an office chair and a bad week in February is the final note: self-management that survives examination, how to find your own triggers, what to do when symptoms flare, and the questions people most often want answered. Read note 04: week to week, flares, and plain answers.